

Supplemental Table 1 – Multivariate logistic regression analysis of associations between *EGFR/EGF* polymorphisms and risk for glioma groups, considering (CA)_n repeat Short ≤ 16 and Long > 16.

Polymorphism	Control	Glioma (Grades 2-4)	OR (95% CI) ¹	Glioblastoma (Grade 4)	OR (95% CI) ¹	Oligodendroglioma (Grades 2-3)	OR (95% CI) ¹
<i>EGFR -216 G/T</i>							
GG	77	91	-	55	-	28	-
GT	74	85	1.17 (0.71-1.93)	45	1.12 (0.60-2.09)	25	1.09 (0.54-2.18)
TT	17	20	1.24 (0.55-2.78)	13	1.38 (0.52-3.61)	5	1.17 (0.36-3.83)
<i>EGFR -191 C/A</i>							
CC	130	140	-	77	-	41	-
CA	32	49	1.85 (1.03-3.33)	30	2.01 (0.98-4.13)	16	1.96 (0.88-4.36)
AA	6	7	0.66 (0.19-2.34)	6	0.84 (0.21-3.48)	1	0.43 (0.04-4.21)
<i>EGFR (CA)_n repeat</i>							
SL	97	76	-	42	-	25	-
LL	38	54	2.21 (1.24-3.93)	32	2.54 (1.24-5.22)	15	2.02 (0.89-4.59)
SS	33	66	3.19 (1.82-5.61)	39	3.12 (1.59-6.14)	18	2.51 (1.15-5.51)
<i>EGF +61 A/G</i>							
AA	57	47	-	30	-	9	-
AG	73	96	1.80 (1.06-3.06)	54	1.70 (0.89-3.22)	32	2.94 (1.24-6.96)
GG	38	53	2.07 (1.11-3.87)	29	1.95 (0.91-4.16)	17	2.89 (1.12-7.46)
Age			1.04 (1.03-1.06)		1.07 (1.05-1.09)		1.02 (1.00-1.04)
Sex							
Female	69	88	-	49	-	25	-
Male	99	108	0.92 (0.59-1.45)	64	1.00 (0.57-1.75)	33	0.94 (0.49-1.79)

Bold-faced values indicate significant difference at 5% level.

¹ OR (95% CI) – Odds ratio with 95% confidence intervals.

Supplemental Table 2 – Multivariate logistic regression analysis of associations between *EGFR/EGF* polymorphisms and risk for glioma groups, considering (CA)_n repeat Short ≤ 18 and Long > 18.

Polymorphism	Control	Glioma (Grades 2-4)	OR (95% CI) ¹	Glioblastoma (Grade 4)	OR (95% CI) ¹	Oligodendroglioma (Grades 2-3)	OR (95% CI) ¹
<i>EGFR -216 G/T</i>							
GG	77	91	-	55	-	28	-
GT	74	85	1.07 (0.65-1.75)	45	1.05 (0.57-1.94)	25	0.95 (0.47-1.92)
TT	17	20	1.10 (0.49-2.46)	13	1.25 (0.48-3.27)	5	0.98 (0.30-3.24)
<i>EGFR -191 C/A</i>							
CC	130	140	-	77	-	41	-
CA	32	49	1.34 (0.76-2.38)	30	1.61 (0.81-3.20)	16	1.29 (0.58-2.85)
AA	6	7	0.68 (0.20-2.33)	6	0.99 (0.25-3.84)	1	0.51 (0.05-4.79)
<i>EGFR (CA)_n repeat</i>							
SL	78	54	-	30	-	14	-
LL	12	19	2.33 (1.00-5.41)	12	2.82 (1.02-7.79)	5	2.49 (0.71-8.68)
SS	78	123	2.21 (1.37-3.55)	71	2.17 (1.21-3.90)	39	2.58 (1.25-5.35)
<i>EGF +61 A/G</i>							
AA	57	47	-	30	-	9	-
AG	73	96	1.68 (0.99-2.85)	54	1.65 (0.87-3.13)	32	2.72 (1.15-6.43)
GG	38	53	1.83 (0.99-3.37)	29	1.83 (0.87-3.84)	17	2.67 (1.03-6.95)
Age			1.04 (1.02-1.06)		1.07 (1.05-1.09)		1.02 (1.00-1.04)
Sex							
Female	69	88	-	49	-	25	-
Male	99	108	0.91 (0.58-1.42)	64	0.97 (0.56-1.69)	33	0.97 (0.51-1.87)

Bold-faced values indicate significant difference at 5% level.

¹ OR (95% CI) – Odds ratio with 95% confidence intervals.

Supplemental Table 3 – Multivariate logistic regression analysis of associations between *EGFR/EGF* polymorphisms and risk for glioma groups, considering the sum of (CA) repeat alleles (Short, sum of repeats < 36; Long, sum of repeats ≥ 36).

Polymorphism	Control	Glioma (Grades 2-4)	OR (95% CI) ¹	Glioblastoma (Grade 4)	OR (95% CI) ¹	Oligodendroglioma (Grades 2-3)	OR (95% CI) ¹
<i>EGFR -216 G/T</i>							
GG	77	91	-	55	-	28	-
GT	74	85	1.06 (0.65-1.72)	45	1.02 (0.55-1.87)	25	0.96 (0.48-1.91)
TT	17	20	1.17 (0.53-2.57)	13	1.37 (0.53-3.53)	5	1.05 (0.33-3.40)
<i>EGFR -191 C/A</i>							
CC	130	140	-	77	-	41	-
CA	32	49	1.38 (0.79-2.42)	30	1.61 (0.81-3.18)	16	1.39 (0.64-3.01)
AA	6	7	0.94 (0.28-3.19)	6	1.29 (0.33-4.99)	1	0.69 (0.07-6.36)
<i>EGFR (CA)_n repeat</i>							
sum ≥ 36	86	77	-	44	-	20	-
sum < 36	82	119	1.48 (0.94-2.32)	69	1.37 (0.78-2.38)	38	1.63 (0.83-3.20)
<i>EGF +61 A/G</i>							
AA	57	47	-	30	-	9	-
AG	73	96	1.69 (1.00-2.84)	54	1.65 (0.88-3.12)	32	2.63 (1.12-6.18)
GG	38	53	1.90 (1.04-3.48)	29	1.87 (0.90-3.89)	17	2.84 (1.10-7.31)
Age			1.04 (1.02-1.05)		1.06 (1.04-1.09)		1.02 (1.00-1.04)
Sex							
Female	69	88	-	49	-	25	-
Male	99	108	0.94 (0.60-1.46)	64	1.00 (0.58-1.72)	33	1.00 (0.53-1.89)

Bold-faced values indicate significant difference at 5% level.

¹ OR (95% CI) – Odds ratio with 95% confidence intervals.

² Sum of (CA) repeat alleles varied from 29 to 41 repeats.

Supplemental Table 4 – Multivariate Cox proportional hazard model analysis of associations between *EGFR/EGF* polymorphisms and glioblastoma patient survival, considering (CA)_n repeat Short ≤ 16 and Long > 16.

Polymorphism	Glioblastoma (Grade 4)	OR (95% CI)¹
<i>EGFR -216 G/T</i>		
GG	33	-
GT	23	0.52 (0.25-1.09)
TT	7	0.56 (0.20-1.62)
<i>EGFR -191 C/A</i>		
CC	41	-
CA	18	0.35 (0.15-0.82)
AA	4	0.41 (0.09-1.91)
<i>EGFR (CA)_n repeat</i>		
SL	16	-
LL	19	0.49 (0.18-1.35)
SS	28	0.42 (0.18-0.95)
<i>EGF +61 A/G</i>		
AA	16	-
AG	28	1.11 (0.49-2.50)
GG	19	2.20 (0.92-5.24)
Age		1.01 (0.97-1.04)
Sex		
Female	25	-
Male	38	0.98 (0.52-1.85)

Bold-faced values indicate significant difference at 5% level.

¹ OR (95% CI) – Odds ratio with 95% confidence intervals.

Supplemental Table 5 – Multivariate Cox proportional hazard model analysis of associations between *EGFR/EGF* polymorphisms and glioblastoma patient survival, considering (CA)_n repeat Short ≤ 18 and Long > 18.

Polymorphism	Glioblastoma (Grade 4)	OR (95% CI)¹
<i>EGFR -216 G/T</i>		
GG	33	-
GT	23	0.62 (0.31-1.25)
TT	7	0.54 (0.19-1.54)
<i>EGFR -191 C/A</i>		
CC	41	-
CA	18	0.37 (0.16-0.82)
AA	4	0.47 (0.12-1.77)
<i>EGFR (CA)_n repeat</i>		
SL	11	-
LL	9	0.57 (0.17-1.93)
SS	43	0.68 (0.30-1.56)
<i>EGF +61 A/G</i>		
AA	16	-
AG	28	1.29 (0.58-2.86)
GG	19	1.95 (0.83-4.59)
Age		1.01 (0.98-1.04)
Sex		
Female	25	-
Male	38	1.02 (0.53-1.96)

Bold-faced values indicate significant difference at 5% level.

¹ OR (95% CI) – Odds ratio with 95% confidence intervals.

Supplemental Table 6 – Multivariate Cox proportional hazard model analysis of associations between *EGFR/EGF* polymorphisms and glioblastoma patient survival, considering the sum of (CA) repeat alleles (Short, sum of repeats < 36; Long, sum of repeats ≥ 36).

Polymorphism	Glioblastoma (Grade 4)	OR (95% CI)¹
<i>EGFR -216 G/T</i>		
GG	33	-
GT	23	0.64 (0.32-1.29)
TT	7	0.49 (0.17-1.38)
<i>EGFR -191 C/A</i>		
CC	41	-
CA	18	0.39 (0.17-0.86)
AA	4	0.41 (0.10-1.71)
<i>EGFR (CA)_n repeat²</i>		
sum ≥ 36	23	-
sum < 36	40	0.85 (0.40-1.80)
<i>EGF +61 A/G</i>		
AA	16	-
AG	28	1.30 (0.58-2.91)
GG	19	1.98 (0.84-4.64)
Age		1.01 (0.98-1.04)
Sex		
Female	25	-
Male	38	0.93 (0.48-1.77)

Bold-faced values indicate significant difference at 5% level.

¹ OR (95% CI) – Odds ratio with 95% confidence intervals.

² Sum of (CA) repeat alleles varied from 29 to 41 repeats.